Study of a JAK3 Inhibitor for the Prevention of Acute Rejection in Kidney Transplant Patients
Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
A new immunosuppressive drug, based on the inhibition of an important enzyme in the immune
system called JAK3, is being developed by Pfizer to prevent transplant rejection. In this
research study, a JAK3 inhibitor or cyclosporine will be given to new kidney transplant
patients for 12 months. Patients will be assigned to one of three treatment groups after
receiving a kidney transplant. Two of the treatment groups will receive 2 different dosing
regimens of the JAK3 inhibitor that will be taken by mouth. The third treatment group will be
a standard-of-care control arm. Patients will continue to take the assigned study medication
for 12 months as well as other standard transplant medications such as prednisone.